Cutting edge: An antibody recognizing ancestral endogenous virus glycoproteins mediates antibody-dependent cellular cytotoxicity on HIV-1-infected cells

Journal of Immunology

Volumn 193, Issue 4, 2014, Pages 1544-1548

  Michaud, Henri Alexandre ^a,b   SenGupta, Devi ^a   De Mulder, Miguel ^a,c   Deeks, Steven G ^a   Martin, Jeffrey N ^a   Kobie, James J ^d   Sacha, Jonah B ^e,f   Nixon, Douglas F ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY HA 137; EPITOPE; HA 137; HUMAN ENDOGENOUS RETROVIRAL K ANTIBODY; PROTEIN ANTIBODY; TRANSMEMBRANE PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; ARTICLE; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CROSS REACTION; DEGRANULATION; DRUG PURIFICATION; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TARGET CELL; VIRUS NEUTRALIZATION;

ANTIBODIES; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ENDOGENOUS RETROVIRUSES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE EVASION; RNA, VIRAL;

EID: 84905995862     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302108     Document Type: Article

References (15)

1. Walker, B. D., and D. R. Burton. 2008. Toward an AIDS vaccine. Science 320: 760-764.
2. Lander, E. S., L. M. Linton, B. Birren, C. Nusbaum, M. C. Zody, J. Baldwin, K. Devon, K. Dewar, M. Doyle, W. FitzHugh, et al.; International Human Genome Sequencing Consortium. 2001. Initial sequencing and analysis of the human genome [Published errata appear in 2001 Nature 412: 565 and 2001 Nature 411: 720]. Nature 409: 860-921.
3. Subramanian, R. P., J. H. Wildschutte, C. Russo, and J. M. Coffin. 2011. Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses. Retrovirology 8: 90.
4. Kurth, R., and N. Bannert. 2010. Beneficial and detrimental effects of human endogenous retroviruses. Int. J. Cancer 126: 306-314.
5. Van Der Kuyl, A. C. 2012. HIV infection and HERV expression: A review. Retrovirology 9 6
6. Garrison, K. E., R. B. Jones, D. A. Meiklejohn, N. Anwar, L. C. Ndhlovu, J. M. Chapman, A. L. Erickson, A. Agrawal, G. Spotts, F. M. Hecht, et al. 2007. T cell responses to human endogenous retroviruses in HIV-1 infection. PLoS Pathog. 3: E165.
7. Michaud, H. A., M. De Mulder, D. SenGupta, S. G. Deeks, J. N. Martin, C. D. Pilcher, F. M. Hecht, J. B. Sacha, and D. F. Nixon. 2014. Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. Retrovirology 11: 10.
8. Esnault, C., O. Heidmann, F. Delebecque, M. Dewannieux, D. Ribet, A. J. Hance, T. Heidmann, and O. Schwartz. 2005. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433: 430-433.
9. Gonzalez-Hernandez, M. J., M. D. Swanson, R. Contreras-Galindo, S. Cookinham, S. R. King, R. J. Noel, Jr., M. H. Kaplan, and D. M. Markovitz. 2012. Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1. J. Virol. 86: 7790-7805.
10. Tosato, G., and J. I. Cohen. 2007. Generation of Epstein-Barr Virus (EBV)-immortalized B cell lines. Curr. Protoc. Immunol. Chapter 7: Unit 7.22.
11. Thobakgale, C. F., L. Fadda, K. Lane, I. Toth, F. Pereyra, S. Bazner, T. Ndung'u, B. D. Walker, E. S. Rosenberg, G. Alter, et al. 2012. Frequent and strong antibody-mediated natural killer cell activation in response to HIV-1 Env in individuals with chronic HIV-1 infection. J. Virol. 86: 6986-6993.
12. Michaud, H. A., T. Gomard, L. Gros, K. Thiolon, R. Nasser, C. Jacquet, J. Hernandez, M. Piechaczyk, and M. Pelegrin. 2010. A crucial role for infectedcell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog. 6: E1000948.
13. Vivier, E., E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini. 2008. Functions of natural killer cells. Nat. Immunol. 9: 503-510.
14. Mohr, E. L., J. Xiang, J. H. McLinden, T. M. Kaufman, Q. Chang, D. C. Montefiori, D. Klinzman, and J. T. Stapleton. 2010. GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. J. Immunol. 185: 4496-4505.
15. Sacha, J. B., I. J. Kim, L. Chen, J. H. Ullah, D. A. Goodwin, H. A. Simmons, D. I. Schenkman, F. von Pelchrzim, R. J. Gifford, F. A. Nimityongskul, et al. 2012. Vaccination with cancer-and HIV infection-associated endogenous retrotransposable elements is safe and immunogenic. J. Immunol. 189: 1467-1479.